Release Summary

Acetylon presents early results of Phase1a/1b trial for citarinostat (ACY-241) in combination with Pomalyst and dexamethasone in patients with relapsed or relapsed-and-refractory multiple myeloma.

Acetylon Pharmaceuticals, Inc.